NVO Novo Nordisk A/S

bearish track record → $44.55 +0.36 (+0.8%)
Mkt Cap $197B P/E 10.4 fwd 13.2 52wk $35.12 - $81.44 23d ago
Est. revisions: +1.3% (1 up, 1 down in 30d)
Backed by structured data (insider trades, analyst ratings, or filings)
Factor Model (net +1.0)

Factor Model

net +1.0 4.1 / 10
Est. Revisions
+0.1
Insider Activity
+0.0
Momentum
+0.8
Analyst Rev.
+0.0
Narrative Gap
+0.5

Wegovy pill surges to $2.2B sales forecast

Watch: Monitor international commercialization of the oral Wegovy pill and upcoming quarterly earnings for sales validation.

Novo Nordisk's oral Wegovy pill hits over 200,000 US weekly prescriptions. UBS raised its sales forecast to $2.2 billion for 2026, up from $1.8 billion. Q1 operating profit jumped 77% year-on-year to DKK32.9 billion, beating estimates by 5%. The obesity drug segment delivered DKK2.26 billion revenue, more than double estimates. Launches outside the US are planned for H2 2026.

Strong prescription growth and profit beat signal Novo's leadership in obesity treatment and robust demand for its oral GLP-1 pill despite market competition.

Our Trades

Full track record →
+17.4%

Long Call · Data Purist — Passed screening filters.

7d · 2026-04-29
+17.4%

Long Call · Trail Blazer — Passed screening filters.

7d · 2026-04-29
+17.4%

Long Call · Wide Runner — Passed screening filters.

7d · 2026-04-29

Evidence

23d ago Wegovy pill on track for blockbuster status as Novo Nordisk navigates crowded GLP-1 market yahoo-finance
36d ago Lilly's obesity pill records modest second week as battle with Novo intensifies yahoo-finance
37d ago NVO Stock Gets Cut to DKK 275 — Yet The Bigger Story Remains Intact yahoo-finance
40d ago A Monthly Weight Loss Shot? Why Pfizer Could Topple Lilly's and Novo's GLP-1 Duopoly yahoo-finance
41d ago Novo Nordisk Announces Partnership with OpenAI yahoo-finance
42d ago Hims and Hers is compounding Ozempic and selling it cheaper than NVO. That's either a brilliant play or a regulatory time bomb. Or both. reddit-stocks
43d ago This Drug Stock Has Crushed the S&P 500 Over the Last Decade yahoo-finance
47d ago Vltava Fund Sold Novo Nordisk (NVO) on Fear of Deteriorating Financial Outlook yahoo-finance
7 older signals
52d ago How do you all feel about the GLP-1 market?
61d ago NVO Price Target 25$ (Analysis)
62d ago NVO has been falling for several days in a row and is now approaching its 52-week low...
64d ago Hims & Hers shifts business model after Novo deal
77d ago 3 Dirt-Cheap Stocks to Buy With $1,000 Right Now
80d ago Novo Nordisk A/S (NVO) Expands Manufacturing to Support Rising Global Demand for GLP-1 Drugs
85d ago Hims & Hers Surprise Rescue: Stock Explodes 40% on GLP-1 Truce
Fundamentals & Data ▾
Novo Nordisk A/S Healthcare · Drug Manufacturers - General
Mkt Cap
$197B
P/E
10.4 fwd 13.2
Beta
0.35
Div Yield
406.00%
52w Range
$35.12 - $81.44
Short Interest
14.0M 0.44%
Days to Cover
0.8 -30%
Technicals downtrend
vs 20d MA
-0.6%
from 52w Hi
-5.4%
Vol (20d)
30%
1w return
+0.6%
1m return
+8.1%
Vol ratio
0.7x
EPS Estimate
$5.17 +1.3% 30d 1up / 1dn
Est. Dispersion
14% 3 analysts
Analyst Target
$47 $40 - $64
Options P/C
0.69
Fund Convergence
moderate Citadel, Renaissance
Financials
Revenue
$96.8B +24% YoY
FCF
$12.0B
Gross Margin
86%
Op Margin
62%
Momentum: accelerating
Top Holders
Citadel $1.6B
Renaissance $125M
15 signals · latest 23d ago

Keep reading the market

Direction shifts, insider clusters, filing red flags, and earnings call changes stay published on the site.

All stocks → Track record → How it works →